Slide 1: Welcome
Welcome Copenhagen May 7, 2022 ESTRO 2022
Slide 2: Agenda – Elekta at ESTRO
Agenda – Elekta at ESTRO Gustaf Salford Delivering on ACCESS 2025 President & CEO Ardie Ermers Future growth in European market Executive Vice President, Region Europe Maurits Wolleswinkel Innovations under ACCESS 2025 Chief Product Officer John Christodouleas, MD, MPH Unity’s clinical evidence deve
Slide 3: Delivering on ACCESS 2025
ESTRO 2022 Delivering on ACCESS 2025 Gustaf Salford President & CEO
Slide 4: Our strategy – ACCESS 2025
Our strategy – ACCESS 2025 Drive Accelerate innovation partner integration with customer across the cancer utilization in mind A world where care eco-system everyone has access to the best cancer care Be the customer Drive adoption lifetime companion across the globe People Resilience & Process Exce
Slide 5: Strategy execution and innovation key for long term performance
Strategy execution and innovation key for long term performance LONG TERM Driver of market FY 21/22 to FY 24/25 FY 20/21 paradigm shift Sustainable ACHIEVED MILESTONES profitable growth Next generation treatment, workflows Adjusting to and customer engagement models to New software platform ’new n
Slide 6: New partnership: Elekta and GE Healthcare
New partnership: Elekta and GE Healthcare Provide hospitals comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy Support mutual health care providers who see clear synergies and advantages with our respective, strong product portfolios Drive growth by j
Slide 7: Strong positions in all business lines and geographies
Strong positions in all business lines and geographies Business lines Americas 29%1 Regions EMEA 35%1 Asia Pacific Oncology 36%1 Informatics Solutions Linac Solutions Brachy Solutions Neuro Solutions Global Service 1 Share of Elekta’s total revenue, first nine months 21/22.
Slide 8: Elekta’s competitiveness and customer edge
Elekta’s competitiveness and customer edge The clear difference why customers want to partner with Elekta Versatile Culture Committed to solutions of innovation partnerships
Slide 9: Future growth in European market
ESTRO 2022 Future growth in European market Ardie Ermers Executive Vice President, Region Europe
Slide 10: Outline
Outline Trends in Europe Elekta’s position in Europe Latest update from Ukraine
Slide 11: Trends in the European radiotherapy market
Trends in the European radiotherapy market • Focus on hypofractionation to catch up on pent up demand after Covid • Looking for long-term partnerships • Patient reported outcome measures (PROM) starting to become standard of care • More combination treatments with increased focus on immunotherapy +
Slide 12: Recovery based on EU fundings and EU/national cancer programs
Recovery based on EU fundings and EU/national cancer programs Several large tenders ongoing funded by EU resilience funds Poland Eastern European Expected Focus on national +50 MEUR cancer programs Italy “Concip” tender Croatia Digitalization driving expected in May Expected investments Spain 160 ME
Slide 13: Strong market position in Europe for Elekta
Strong market position in Europe for Elekta • Strong market share gain in Europe1 by complete solutions with strong service track record • Philips and GE partnership showing impact for customers looking for end to end solutions • Unity – an attractive solution to differentiate and drive ultra hypofr
Slide 14: Courageous cancer care work in war-torn Ukraine
Courageous cancer care work in war-torn Ukraine • Almost all hospitals damaged • Now all Elekta equipment by the war up and running • Oncologists in Dnipro treating • Represented by up to 160 patients per day local distributor • Some refugees with ongoing cancer • Active training for treatment retur
Slide 15: Welcome to Elekta booth, Hall C
Welcome to Elekta booth, Hall C >3,000 pre-booked customers visiting ESTRO= x2 more compared to ESTRO 2021 >100 exhibitors
Slide 16: Innovations under ACCESS 2025
ESTRO 2022 Innovations under ACCESS 2025 Maurits Wolleswinkel Chief Product Officer
Slide 17: Outline
Outline Our innovation strategy recap Progress to date Software in focus Latest collaboration update
Slide 18: Innovation agenda related to ACCESS 2025
Innovation agenda related to ACCESS 2025 Digital Drive transformation Accelerate innovation Interoperability partner integration with customer New software across the cancer Co-create utilization in mind platform A world where care eco-system partnerships development everyone has access to the best
Slide 19: What does access to the best cancer care mean?
What does access to the best cancer care mean? 2025 MILESTONE Availability +300m people 1 of care to gain access to RT via 800 to 1000 additional Elekta Linacs in underserved markets Elevation 2x to 4x 2 of care double the clinical usage of short course treatment (hypofractionation) and quadruple th
Slide 20: ACCESS 2025 drives our product strategy
ACCESS 2025 drives our product strategy Comprehensive Oncology Care Clinical decision support Resource optimization Solutions Patient’s role in care pathway Mobility of care Software | Services Radiation Therapy Integration and expansion Workflow efficiency Treatment of imaging and automation Soluti
Slide 21: Three focus areas within innovation
Three focus areas within innovation 1 Personalized Precision Elevated Productivity 2 Comprehensive Oncology Care Clinical decision support Resource optimization Solutions Patient’s role in care pathway Mobility of care Software | Services Radiation Therapy 3 Integrated Informatics Integration and ex
Slide 22: Delivering on innovation program described at CMD in June 2021
Delivering on innovation program Capital Markets Day described at CMD in June 2021 2021 Elekta is accelerating innovation investments Digital transformation program
Slide 23: Towards a single software foundation
Towards a single software foundation Linacs MR/RT Neuro Brachy Informatics Joint software foundation to streamline workflow, drive automation and productivity
Slide 24: Recent product releases, and digital transformation at full speed
Recent product releases, and digital transformation at full speed Gross R&D expenses as % of sales Series of innovations in the next 3 years 15% MOSAIQ Plaza expansion and RWE/PRO Kaiku 10% Software SmartClinic expansion New METRIQ/outcomes Monaco 6 / MOSAIQ 3 Workflow & adaptive treatment apps 5% 2
Slide 25: Updates on various innovation tracks
Updates on various innovation tracks 1 Precision New Leksell Gamma Knife Verena Schiller Clinical evidence development Unity MR-Linac John Christodouleas, MD, MPH
Slide 26: Unity comprehensive motion management program on track
1 Precision Unity comprehensive motion management program on track Comprehensive Optimised high field imaging Real-time 3D structure tracking & gating motion management 3D Vane Free Breathing Delivered First install ongoing
Slide 27: Harmony well underway
2 Productivity Harmony well underway Productivity validated: <10 min time slots Clinical versatility validated; >30 indications incl SBRT Margin expansion of >10 percentage points MR-Linac Unity segment Versa Premium HD segment Harmony Performance Pro segment Value Harmony segment
Slide 28: Software in focus: elevate access, transition to mobility and orchestration
2 Productivity Software in focus: elevate access, transition to mobility and orchestration of complex treatments Challenge: Our solutions: Increased SmartClinic complexity Untap knowledge, access in customer workflows Future proofing Stepping stone to new workflow MOSAIQ Plaza management solutions a
Slide 29: Case study: SmartClinic
2 Productivity Case study: SmartClinic Mobility Notification Visualization
Slide 30: Case study: SmartClinic workflows are significantly more efficient
Case study: SmartClinic workflows are significantly more efficient Customers at GenXRT: SmartClinic streamlines processes and with SmartBoard makes sure that things can’t get missed SmartClinic replaces paper processes with smart forms and this technology is for everyone Customers at Centro Medico A
Slide 31: Software in focus: winning across the globe
Software in focus: winning across the globe Installed systems +80 installed SmartClinic systems Orders won +170 orders won to date Adoption of SaaS/Cloud Rapidly growing in orders
Slide 32: Integrated informatics is about clinical discovery and big data
Integrated informatics is about clinical 3 Integrated Informatics discovery and big data 50 NHS trust hospitals ProKnow acquiring ProKnow Quality control – powerful platform leverage in our software suite
Slide 33: Update on Philips partnership
Update on Philips partnership Imaging for Elevate Unity MR-Linac capabilities motion management Precision On track to establish full Offer integrated pathway/MDT solutions interoperability of within MOSAIQ Plaza eco-system joint solution this FY Jointly streamline automate adaptive On track to launc
Slide 34: Partnership with the Netherlands Cancer Institute (AVL/NKI)
Partnership with the Netherlands Cancer Institute (AVL/NKI) 10 years agreement Transition of Philips TPS, to joint new software solution Co-create adaptive and personalised workflows Treatment delivery advancements in both linac and MR-linac First dedicated AI-in-RT lab is live; POP-ART
Slide 35: Innovation agenda on track
Innovation agenda on track Accelerated innovation investments and partnerships driving future growth R&D as % of sales to stabilize On track to realise our product strategy, to support growth and margin expansion
Slide 36: Unity’s clinical evidence development journey
ESTRO 2022 Unity’s clinical evidence development journey John Christodouleas, MD, MPH SVP of Medical Affairs
Slide 37: Sixteen ongoing clinical trials testing value of Unity
Sixteen ongoing clinical trials testing value of Unity 2 brain trials (glioblastoma) 4 head & neck trials 1 thoracic trial 5 abdominal trials 4 pelvis trials
Slide 38: Deeper dive into some cancer types and purposes
Deeper dive into some cancer types and purposes United Radiopanc Hermes
Slide 39: Reduce radiated target volume to lower side effects
United (glioblastoma) Reduce radiated target volume to lower side effects Standard target ? Dr. Detsky Dr. Sahgal Can uncertainty margins United target around the tumor be safely reduced from 15mm to 5mm Transverse plane
Slide 40: Challenge: brain tumors “migrate” during therapy
United (glioblastoma) Challenge: brain tumors “migrate” during therapy Day 0 Day 10 Day 20 Tumor Transverse plane Unity advantage: brain tumor migration visible ─ not visible on CT ─ MR images adapted from Steward J et al. IJROBP. 2021.and courtesy of Chia-Lin Tseng.
Slide 41: Intensify treatment to improve cure rates
Radiopanc (pancreas) Intensify treatment to improve cure rates Dr. Meijer ? Can the dose to pancreas tumor be safely escalated to 2x the current standard Transverse plane of care MR image courtesy of Filippo Alongi.
Slide 42: Challenge: pancreas moves with respiratory motion
Radiopanc (pancreas) Challenge: pancreas moves with respiratory motion Coronal Sagittal Coronal plane Sagittal plane Unity advantage: respiratory motion visible ─ not visible on CT ─
Slide 43: Improve quality of life and lower healthcare costs
Hermes (prostate) Improve quality of life and lower healthcare costs Sagittal plane ? Dr. Tree Can the intermediate risk prostate cancer be safely treated in 2 sessions MR image courtesy of Uulke van der Heide
Slide 44: Challenge: the prostate swells during therapy
Hermes (prostate) Challenge: the prostate swells during therapy Prostate volume changes over time Unity advantage: prostate swelling visable ─ not visible on CT ─ MR images courtesy of Alison Tree. Figure from Alexander S et al. presented at SABR Consortium 2021
Slide 45: First ongoing clinical trials to be completed 2023
First ongoing clinical trials to be completed 2023 Brain trials Estimated year of completion • MR guided adapted fractionated SRT is safe in patients with brain metastases in NSCLC. Guangzhou, China 2023 • UNITED - Margin reduction using MR adaptive RT is safe and will reduce toxicity in GBM. Sunnyb
Slide 46: Evidence of all type drive adoption and differential reimbursement
Evidence of all type drive adoption and differential reimbursement Increasing levels of clinical evidence Superiority Clinical safety 32 Growing number of Unity publications and effectiveness peer-reviewed articles reporting clinical patient treatment New concept exploration, treatment >450 peer-rev
Slide 47: Powerful infrastructure for the evidence development journey of Unity
Powerful infrastructure for the evidence development journey of Unity >60 ~700 11 >2,600 consortium sites researchers sites sharing data patients accrued
Slide 48: Yesterday’s Neuro launch
ESTRO 2022 Yesterday’s Neuro launch Verena Schiller President Neuro Solutions
Slide 49: Meet Elekta Esprit
Meet Elekta Esprit Dedication in design Designed solely for accurate and precise intracranial stereotactic radiosurgery (SRS) Patients at the center Personalized treatment for improved quality of life Proven beyond compare Real-world evidence that is transforming treatment protocols and redefining s
Slide 50: Feature at a glance
Feature at a glance <1 minute per treatment plan with New modern and Lightning premium design Superior visualization of brain anatomy with Leksell Vantage 73% of clinical peer-reviewed evidence Mounted monitor Updated patient bed with ergonomic side protections New operator experience Minimal deskto
Slide 51: High ROI potential
High ROI potential 99% average uptime1 Higher ROI <10 min QA time per day Uptime 512 average patients per year3 > 1000 throughput potential per year2 Patient throughput
Slide 52: Q&A
Q&A Gustaf Salford President & CEO Ardie Ermers ESTRO Executive Vice President, Region Europe Maurits Wolleswinkel 2022 Chief Product Officer John Christodouleas MD, MPH, Senior Vice President of Medical Affairs Verena Schiller President Neuro Solutions